Compare Amgen, Inc. (AMGN) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Global X Autonomous & Electric Vehicles — how do they compare? Amgen, Inc. trades at $415.07 (market cap $225.15B), while Global X Autonomous & Electric Vehicles trades at $35.75. The key difference: Amgen, Inc. pays a 2.42% dividend while Global X Autonomous & Electric Vehicles pays none, and Amgen, Inc. is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| AMGN | DRIV | |
|---|---|---|
Market Cap | $225.15B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.84 | $42.53 |
52-Week Low | $271.18 | $25.23 |
Enterprise Value | $268.47B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.84, up 0.85% today, near its R1 resistance of $418. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, and revenue exceeding $10 billion. Analyst consensus is bullish with 23 Buy ratings, a $392.53 price target, and technical indicators signaling a bullish trend from moving averages, though RSI levels suggest overbought conditions.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high debt levels and competitive pressures. The stock offers a dividend yield supported by consistent payouts, with investor sentiment bolstered by recent earnings outperformance and media coverage highlighting growth prospects.
DRIV trades at $35.92, up 1.07% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum, supported by positive sentiment around electric vehicle and autonomous driving exposure. Recent news highlights global EV sales growth and China's expanding market ambitions, benefiting DRIV's sector focus.
The outlook remains positive given sector tailwinds, but risks include regulatory delays and competitive pressures. Analyst consensus leans bullish, with DRIV outperforming peers year-to-date. Key catalysts include continued EV adoption and autonomous technology advancements, though investors should monitor fuel price volatility and trade policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
